drugset / Trial / NCT00382135

A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg

NCT00382135

Phase 4 Completed 282 enrolled Eli Lilly and Company ICOS Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel design study to evaluate effects on semen characteristics after 40 weeks of daily dosing with 20 mg tadalafil.

Timeline

Start
2003-11
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tadalafil Small molecule 20 mg Oral

Indications